Patents by Inventor Adam D. Hughes

Adam D. Hughes has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Diamide compounds having muscarinic receptor antagonis and beta2 adrenergic receptor agonist activity
    Patent number: 10138220
    Abstract: The invention relates to a pharmaceutical composition comprising an isotonic aqueous solution comprising from about 0.05 ?g/mL to about 10 mg/mL of a compound of formula I: or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: April 23, 2018
    Date of Patent: November 27, 2018
    Assignee: Theravance Respiratory Company, LLC
    Inventors: Adam D. Hughes, Daniel Byun, Yan Chen, Melissa Fleury, John R. Jacobsen, Eric L. Stangeland, Richard D. Wilson, Rose Yen
  • Neprilysin inhibitors
    Patent number: 10130642
    Abstract: In one aspect, the invention relates to compounds having the formula: where R1-R6, a, b, Z, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.
    Type: Grant
    Filed: June 30, 2017
    Date of Patent: November 20, 2018
    Assignee: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Melissa Fleury, Roland Gendron, Adam D. Hughes
  • NEPRILYSIN INHIBITORS
    Publication number: 20180327350
    Abstract: In one aspect, the invention relates to compounds having the formula XII: where Ra, Rb, R2, R7, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds described herein are prodrugs of compounds having neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising these compounds; methods of using these compounds; and processes and intermediates for preparing these compounds.
    Type: Application
    Filed: December 15, 2017
    Publication date: November 15, 2018
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Melissa Fleury, Adam D. Hughes
  • Neprilysin inhibitors
    Patent number: 10123984
    Abstract: In one aspect, the invention relates to compounds having the formula: where R1-R6, a, b, and Z are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.
    Type: Grant
    Filed: May 12, 2017
    Date of Patent: November 13, 2018
    Assignee: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Adam D. Hughes, Erik Fenster, Melissa Fleury, Roland Gendron, Edmund J. Moran
  • Crystalline(2S,4R)-5-(5?-chloro-2?-fluoro-[1,1?-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof
    Patent number: 10100021
    Abstract: In one aspect, the invention relates to a crystalline form of the structure: or a pharmaceutically acceptable salt thereof, having neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising this crystalline form; methods of using this crystalline form and its soluble form (I); and processes for preparing soluble (I) and crystalline (I?) forms.
    Type: Grant
    Filed: March 7, 2017
    Date of Patent: October 16, 2018
    Assignee: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Adam D. Hughes, Melissa Fleury, Miroslav Rapta, Venkat R. Thalladi, Gene Timothy Fass, Michael Simeone
  • NEPRILYSIN INHIBITORS
    Publication number: 20180237423
    Abstract: In one aspect, the invention relates to compounds having the formula: where X, Ra, Rb, R2, and R7 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds are prodrugs of compounds having neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising these compounds; methods of using these compounds; and processes and intermediates for preparing these compounds.
    Type: Application
    Filed: December 14, 2017
    Publication date: August 23, 2018
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Melissa Fleury, Adam D. Hughes
  • Neprilysin inhibitors
    Patent number: 10053417
    Abstract: In one aspect, the invention relates to compounds having the formula: where R1-R5 and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.
    Type: Grant
    Filed: November 8, 2017
    Date of Patent: August 21, 2018
    Assignee: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Erik Fenster, Melissa Fleury, Adam D. Hughes
  • (2R,4R)-5-(5'-CHLORO-2'-FLUOROBIPHENYL-4-YL)-2-HYDROXY-4-[(5-METHYLOXAZOLE-2-CARBONYL)AMINO]PENTANOIC ACID
    Publication number: 20180228774
    Abstract: In one aspect, the invention relates to a compound of the structure: or a pharmaceutically acceptable salt thereof, and a crystalline form of this compound, having neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising this compound; methods of using this compound; and processes for preparing this compound.
    Type: Application
    Filed: December 14, 2017
    Publication date: August 16, 2018
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Melissa Fleury, Adam D. Hughes, Anne-Marie Beausoleil, Erik Fenster, Venkat R. Thalladi, Miroslav Rapta
  • NEPRILYSIN INHIBITORS
    Publication number: 20180193338
    Abstract: In one aspect, the invention relates to compounds having the formula I: where R1, R2a, R2b, and R3-R6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising these compounds; methods of using these compounds; and processes and intermediates for preparing these compounds.
    Type: Application
    Filed: November 8, 2017
    Publication date: July 12, 2018
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Melissa Fleury, Anne-Marie Beausoleil, Adam D. Hughes, Daniel D. Long, Donna A.A. Wilton
  • NEPRILYSIN INHIBITORS
    Publication number: 20180194718
    Abstract: In one aspect, the invention relates to compounds having the formula: where R1-R5 and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.
    Type: Application
    Filed: November 8, 2017
    Publication date: July 12, 2018
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Erik Fenster, Melissa Fleury, Adam D. Hughes
  • NEPRILYSIN INHIBITORS
    Publication number: 20180194776
    Abstract: In one aspect, the invention relates to compounds having the formula: where R1-R6, a, b, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.
    Type: Application
    Filed: November 8, 2017
    Publication date: July 12, 2018
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Roland Gendron, Adam D. Hughes
  • NEPRILYSIN INHIBITORS
    Publication number: 20180194757
    Abstract: In one aspect, the invention relates to compounds having the formula: where R1, R2, R3, R4, and R5 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
    Type: Application
    Filed: October 24, 2017
    Publication date: July 12, 2018
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Roland Gendron, Adam D. Hughes
  • Neprilysin inhibitors
    Patent number: 10005740
    Abstract: In one aspect, the invention relates to compounds having the formula I: where R1-R6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising these compounds; methods of using these compounds; and processes and intermediates for preparing these compounds.
    Type: Grant
    Filed: September 6, 2017
    Date of Patent: June 26, 2018
    Assignee: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Melissa Fleury, Anne-Marie Beausoleil, Adam D. Hughes, Daniel D. Long, Donna A. A. Wilton
  • Neprilysin inhibitors
    Patent number: 9981999
    Abstract: In one aspect, the invention relates to compounds having the formula X: where Ra, Rb, R2, R7, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds described herein are prodrugs of compounds having neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising these compounds; methods of using these compounds; and processes and intermediates for preparing these compounds.
    Type: Grant
    Filed: May 8, 2017
    Date of Patent: May 29, 2018
    Assignee: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Adam D. Hughes, Melissa Fleury
  • Diamide compounds having muscarinic receptor antagonist and Beta2 adrenergic receptor agonist activity
    Patent number: 9975875
    Abstract: This invention relates to a compound of formula I: or a pharmaceutically acceptable salt thereof. Such compounds possess both muscarinic receptor antagonist and ?2 adrenergic receptor agonist activities. The invention also relates to pharmaceutical compositions comprising such compounds, processes and intermediates for preparing such compounds, and methods of using such compounds as bronchodilating agents to treat pulmonary disorders.
    Type: Grant
    Filed: August 18, 2017
    Date of Patent: May 22, 2018
    Assignee: Theravance Respiratory Company, LLC
    Inventors: Adam D. Hughes, Daniel Byun, Yan Chen, Melissa Fleury, John R. Jacobsen, Eric L. Stangeland, Richard D. Wilson, Rose Yen
  • NEPRILYSIN INHIBITORS
    Publication number: 20180118696
    Abstract: In one aspect, the invention relates to compounds having the formula I: where R1-R6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising these compounds; methods of using these compounds; and processes and intermediates for preparing these compounds.
    Type: Application
    Filed: September 6, 2017
    Publication date: May 3, 2018
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Melissa Fleury, Anne-Marie Beausoleil, Adam D. Hughes, Daniel D. Long, Donna A.A. Wilton
  • NEPRILYSIN INHIBITORS
    Publication number: 20180105503
    Abstract: In one aspect, the invention relates to compounds having the formula: where R1, R2, R3, X, R4, R5, and R6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
    Type: Application
    Filed: August 29, 2017
    Publication date: April 19, 2018
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Melissa Fleury, Roland Gendron, Adam D. Hughes, Jane Schmidt
  • NEPRILYSIN INHIBITORS
    Publication number: 20180050052
    Abstract: In one aspect, the invention relates to compounds having the formula: where R1-R6, a, b, Z, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.
    Type: Application
    Filed: June 30, 2017
    Publication date: February 22, 2018
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Melissa Fleury, Roland Gendron, Adam D. Hughes
  • NEPRILYSIN INHIBITORS
    Publication number: 20180051023
    Abstract: In one aspect, the invention relates to compounds having the formula: where R1, R2a, R2b, R3-R6, a, b, Z, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.
    Type: Application
    Filed: June 30, 2017
    Publication date: February 22, 2018
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Melissa Fleury, Roland Gendron, Adam D. Hughes, Cameron Smith
  • Neprilysin inhibitors
    Patent number: 9884807
    Abstract: In one aspect, the invention relates to compounds having the formula XII: where Ra, Rb, R2, R7, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds described herein are prodrugs of compounds having neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising these compounds; methods of using these compounds; and processes and intermediates for preparing these compounds.
    Type: Grant
    Filed: April 28, 2017
    Date of Patent: February 6, 2018
    Assignee: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Melissa Fleury, Adam D. Hughes